Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

NCT02558894 PHASE2 COMPLETED Results posted

A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination with Tremelimumab in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Details

Lead sponsor	AstraZeneca
Phase	PHASE2
Status	COMPLETED
Enrolment	65
Start date	Mon Nov 16 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jun 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

• MEDI4736 monotherapy
• tremelimumab+MEDI4736

Countries

Netherlands, Germany, South Korea, Canada, United States, Spain